Beiersdorf
This article was originally published in The Rose Sheet
Executive Summary
Hamburg, Germany-based marketer of Eucerin, Nivea and La Prairie skin-care lines reported a 38% drop in earnings to €380 mil., or $517 mil., for fiscal 2009. Sales in its consumer segment totaled roughly €5 bil., or $6.8 bil., a 2.2% decline from prior year, with currency fluctuations. Eucerin led the way for Beiersdorf's lines, with 6.5% global growth. Nivea posted gain of 1.3%, while firm's luxury La Prairie franchise experienced an 8.7% decline. Sales in the firm's consumer segment rose 13.3% in Latin America for the year. In a March 4 release, Chairman Thomas-B. Quass suggested firm is well-positioned for new market reality following the economic crisis, but noted it will "need to be even more flexible and focus even more strongly on [its] core competencies in the future.
You may also be interested in...
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.